MARKET

NYMX

NYMX

Nymox Pharm
NASDAQ
0.4200
+0.0550
+15.07%
Opening 14:14 09/30 EDT
OPEN
0.3650
PREV CLOSE
0.3650
HIGH
0.4200
LOW
0.3650
VOLUME
62.25K
TURNOVER
21.03K
52 WEEK HIGH
2.150
52 WEEK LOW
0.1850
MARKET CAP
38.33M
P/E (TTM)
-3.5928
1D
5D
1M
3M
1Y
5Y
Nymox gets FDA feedback on NDA resubmission for lead asset
Nymox Pharmaceutical (NASDAQ:NYMX), a biotech fo...
Seekingalpha · 09/13 13:55
NYMOX Provides Current Update
IRVINE, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on business developments. The Company has corresponded with and has met with the FDA during the past few months. The a...
GlobeNewswire · 09/13 13:30
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 09/02 17:56
12 Health Care Stocks Moving In Monday's Intraday Session
 
Benzinga · 08/29 17:41
Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 08/17 11:01
11 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 07/25 12:16
Nymox Pharmaceutical up 37% as it assures shareholders company is well funded
Nymox Pharmaceutical has informed its shareholders that the company is well funded and its business plans are "...
Seekingalpha · 07/15 15:39
BRIEF-Nymox Updates Shareholders
BRIEF-Nymox Updates Shareholders
Reuters · 07/15 14:59
More
About NYMX
Nymox Pharmaceutical Corporation is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (prostate enlargement, BPH) and for low-grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company’s lead drug candidate for BPH FT has completed Phase III development in more than 70 clinical centers in the United States. FT has completed a phase II trial in the United States. It has also developed the AlzheimAlert test. The Company operates in Canada, the United States and Switzerland.

Webull offers kinds of Nymox Pharmaceutical Corp stock information, including NASDAQ:NYMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NYMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NYMX stock methods without spending real money on the virtual paper trading platform.